Hubert Schrezenmeier
#144,977
Most Influential Person Now
Researcher
Hubert Schrezenmeier's AcademicInfluence.com Rankings
Hubert Schrezenmeierbiology Degrees
Biology
#10474
World Rank
#13807
Historical Rank
Cell Biology
#496
World Rank
#508
Historical Rank
Molecular Biology
#1526
World Rank
#1553
Historical Rank
Neuroscience
#1623
World Rank
#1674
Historical Rank
Download Badge
Biology
Why Is Hubert Schrezenmeier Influential?
(Suggest an Edit or Addition)Hubert Schrezenmeier's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (2006) (868)
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) (696)
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. (2008) (550)
- Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. (2007) (506)
- T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells (1988) (441)
- Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. (1998) (425)
- Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. (2012) (418)
- Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. (1991) (389)
- Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. (2003) (312)
- Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria (2013) (307)
- Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). (2007) (305)
- Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. (2006) (285)
- Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. (2008) (281)
- Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components (2012) (259)
- Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. (2007) (259)
- Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. (2013) (250)
- Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. (2000) (249)
- Mesenchymal stem cells for clinical application (2010) (248)
- TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. (2014) (204)
- A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage (2012) (193)
- Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. (2021) (189)
- Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients (2021) (189)
- Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. (1999) (188)
- Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. (2015) (187)
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. (2019) (180)
- Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry (2014) (177)
- High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. (2013) (177)
- Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. (2013) (173)
- A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. (1995) (173)
- GMP-Compliant Isolation and Large-Scale Expansion of Bone Marrow-Derived MSC (2012) (168)
- Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood–derived platelets and apheresis platelets (2007) (164)
- Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups (2012) (159)
- Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. (2012) (152)
- A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage (2014) (147)
- Telomerase gene mutations are associated with cirrhosis formation (2011) (146)
- Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. (1994) (140)
- Carboxylated Superparamagnetic Iron Oxide Particles Label Cells Intracellularly Without Transfection Agents (2008) (140)
- A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes (2004) (137)
- Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors (2010) (135)
- Deficiency of innate and acquired immunity caused by an IKBKB mutation. (2013) (133)
- Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. (2015) (132)
- Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. (2013) (128)
- Similar outcome of upfront‐unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT (2015) (123)
- Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. (2019) (123)
- Results of intracoronary stem cell therapy after acute myocardial infarction. (2010) (123)
- A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. (2011) (123)
- How much blood is needed? (2011) (119)
- Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party (1993) (118)
- Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial (2018) (117)
- Buffy‐coat‐derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? (2010) (117)
- Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria (2012) (117)
- GMP-Compliant Isolation and Expansion of Bone Marrow-Derived MSCs in the Closed, Automated Device Quantum Cell Expansion System (2013) (116)
- Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. (2013) (115)
- Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). (2007) (112)
- Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants (2021) (109)
- Effectiveness of Immunosuppressive Therapy in Older Patients with Aplastic Anemia (1999) (107)
- Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia (2006) (107)
- Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients (2010) (106)
- Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. (1995) (105)
- Phenotypic Characterization of Mesenchymal Stem Cells from Various Tissues (2008) (105)
- Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate (2013) (105)
- Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. (2017) (103)
- Eosinophils Oxidize Damage-Associated Molecular Pattern Molecules Derived from Stressed Cells1 (2009) (101)
- Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. (1990) (101)
- Recent improvement in outcome of unrelated donor transplantation for aplastic anemia (2008) (98)
- Synthesis and biomedical applications of functionalized fluorescent and magnetic dual reporter nanoparticles as obtained in the miniemulsion process (2006) (97)
- Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant (2015) (96)
- T lymphocyte activation by staphylococcal enterotoxins: role of class II molecules and T cell surface structures. (1989) (90)
- The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. (2003) (88)
- Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering. (1986) (86)
- Outcome of Pregnancy and Disease Course among Women with Aplastic Anemia Treated with Immunosuppression (2002) (86)
- Influence of Donor/Recipient Sex Matching on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia (2006) (86)
- Human B cells differentiate into granzyme B‐secreting cytotoxic B lymphocytes upon incomplete T‐cell help (2012) (86)
- Anticoagulant-induced Pseudothrombocytopenia and Pseudoleucocytosis (1995) (84)
- Current Results of Bone Marrow Transplantation in Patients with Acquired Severe Aplastic Anemia (2000) (82)
- Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA (2009) (82)
- Drug induced immune haemolytic anaemia in the Berlin Case‐Control Surveillance Study (2011) (81)
- A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT. (2013) (79)
- Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. (2019) (74)
- Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single‐lineage marrow failure: a pilot study and a survey from the EBMT WPSAA (2010) (72)
- Dual effects of arsenic trioxide (As2O3) on non‐acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation (2002) (72)
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe (2002) (70)
- Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study (2012) (70)
- Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (70)
- Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload (2012) (70)
- Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material (2011) (69)
- Automatic interface‐controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device (2011) (68)
- Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. (2018) (67)
- Clonal analysis of human T cell activation by the Mycoplasma arthritidis mitogen (MAS) (1988) (65)
- The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. (2020) (61)
- Haemopoietic growth factors in aplastic anaemia: a cautionary note (1994) (61)
- Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis (2005) (60)
- Targeted therapy with eculizumab for inherited CD59 deficiency. (2014) (60)
- Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportionof transfused units, and clinical follow-up (2009) (59)
- Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. (2018) (59)
- Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. (1996) (58)
- mRNA-Mediated Gene Delivery Into Human Progenitor Cells Promotes Highly Efficient Protein Expression (2007) (57)
- Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. (1993) (57)
- CD4+ T Cell–Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme B–Expressing Regulatory B Cells in HIV Patients (2015) (53)
- Supportive care in severe and very severe aplastic anemia (2013) (53)
- Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria (2020) (53)
- Effect of functionalised fluorescence-labelled nanoparticles on mesenchymal stem cell differentiation. (2010) (52)
- B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients (2021) (52)
- SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination (2021) (51)
- The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a. (2003) (50)
- Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation (2012) (50)
- Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry (2016) (47)
- B Cell Numbers Predict Humoral and Cellular Response Upon SARS–CoV‐2 Vaccination Among Patients Treated With Rituximab (2021) (47)
- Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial (2013) (47)
- Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes (2011) (45)
- Recipients potentially infected with parvovirus B19 by red blood cell products (2011) (44)
- Comparative Analysis of Different Platelet Lysates and Platelet Rich Preparations to Stimulate Tendon Cell Biology: An In Vitro Study (2018) (44)
- Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients (2022) (44)
- Topical Transforming Growth Factor-&bgr;3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors (2001) (43)
- The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. (1999) (42)
- Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing (2020) (41)
- Drug-induced agranulocytosis in the Berlin case–control surveillance study (2014) (41)
- Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside (2004) (40)
- Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry (2020) (40)
- International Forum on GMP‐grade human platelet lysate for cell propagation: summary (2018) (40)
- Transportation conditions for prompt use of ex vivo expanded and freshly harvested clinical-grade bone marrow mesenchymal stromal/stem cells for bone regeneration. (2014) (39)
- GMP-adapted overexpression of CXCR4 in human mesenchymal stem cells for cardiac repair. (2013) (39)
- A phase I/II trial of recombinant human interleukin‐6 in patients with aplastic anaemia (1995) (38)
- Thrombopoietin serum levels in patients with aplastic anaemia: correlation with platelet count and persistent elevation in remission (1998) (38)
- High levels of thrombopoietin in sera of patients with essential thrombocythemia: Cause or consequence of abnormal platelet production? (1998) (38)
- S100A4 and Uric Acid Promote Mesenchymal Stromal Cell Induction of IL-10+/IDO+ Lymphocytes (2014) (38)
- Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls (2012) (37)
- The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia (2007) (37)
- Labeling of mesenchymal stromal cells with iron oxide-poly(l-lactide) nanoparticles for magnetic resonance imaging: uptake, persistence, effects on cellular function and magnetic resonance imaging properties (2011) (37)
- Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. (2021) (37)
- Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. (2020) (37)
- Essential components for ex vivo proliferation of mesenchymal stromal cells. (2014) (37)
- Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test (2012) (37)
- The power of DNA double‐strand break (DSB) repair testing to predict breast cancer susceptibility (2012) (37)
- Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. (2016) (36)
- Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH. (2005) (36)
- A regulatory role for the CD4 and CD8 molecules in T cell activation. (1988) (36)
- Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia (2002) (36)
- Crucial Role of IL1beta and C3a in the In Vitro-Response of Multipotent Mesenchymal Stromal Cells to Inflammatory Mediators of Polytrauma (2015) (36)
- Mitogenic activity of staphylococcal protein A is due to contaminating staphylococcal enterotoxins. (1987) (35)
- Serum erythropotietin and serum transferrin receptor levels in aplastic anaemia (1994) (34)
- mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects (2021) (34)
- Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19 (2021) (33)
- Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. (2005) (33)
- Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H–like Protein 1 Reveal Functional Determinants of Complement Regulation (2016) (33)
- SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data (2021) (31)
- The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. (2009) (30)
- Experimental blunt chest trauma-induced myocardial inflammation and alteration of gap-junction protein connexin 43 (2017) (30)
- Drugs that inhibit complement. (2012) (30)
- GMP-Compliant Expansion of Clinical-Grade Human Mesenchymal Stromal/Stem Cells Using a Closed Hollow Fiber Bioreactor. (2016) (30)
- Effect of high-dose irradiation on human bone-marrow-derived mesenchymal stromal cells. (2015) (30)
- Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)‐and anti‐CD95‐induced apoptosis in myeloid cells (2004) (29)
- Fracture Healing Is Delayed in Immunodeficient NOD/scid‑IL2Rγcnull Mice (2016) (29)
- Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO‐incompatible red blood cell transfusion (2015) (29)
- First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001‐2012 (2018) (29)
- Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. (2016) (28)
- Robust and durable serological response following pediatric SARS-CoV-2 infection (2022) (28)
- Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. (2019) (28)
- Activation of human T lymphocytes III. Triggering of bystander cytotoxicity in cytotoxic T cell clones by antibodies against the T3 antigen or by a calcium ionophore (1985) (27)
- Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. (2019) (27)
- A new blood group antigen is defined by anti‐CD59, detected in a CD59‐deficient patient (2014) (27)
- Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party (2010) (27)
- Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMT (2010) (26)
- Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT) (2020) (26)
- Paroxysmal Nocturnal Haemoglobinuria: A Replacement of Haematopoietic Tissue? (2000) (26)
- Cerebral Ischemic Infarction in Paroxysmal Nocturnal Hemoglobinuria (2005) (26)
- The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004 (2009) (26)
- Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study (2017) (25)
- Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1 (2019) (25)
- An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection (2020) (25)
- Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. (2020) (24)
- Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte‐colony‐stimulating factor: safety, efficacy, and graft performance (2016) (24)
- HLA-E polymorphisms in hematopoietic stem cell transplantation. (2011) (24)
- High prevalence of GBV‐C/HGV among relatives of GBV‐C/HGV‐positive blood donors in blood recipients and in patients with aplastic anemia (2004) (24)
- Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies (2009) (23)
- Evaluation of platelet‐rich plasma and hydrostatic pressure regarding cell differentiation in nucleus pulposus tissue engineering (2013) (23)
- Do CD4 or CD8 molecules provide a regulatory signal in T-cell activation? (1988) (22)
- Inactivation of a T cell receptor-associated GTP-binding protein by antibody-induced modulation of the T cell receptor/CD3 complex (1988) (21)
- Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors (2021) (21)
- Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial) (2015) (21)
- Immunotherapy for cancer: promoting innate immunity. (2009) (21)
- Altered increase in STAT1 expression and phosphorylation in severe COVID‐19 (2021) (20)
- In‐frame triplet deletions in RHD alter the D antigen phenotype (2006) (20)
- Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)—report on phases I and II (2016) (20)
- Direct and indirect effects of functionalised fluorescence-labelled nanoparticles on human osteoclast formation and activity. (2011) (20)
- Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin. (2015) (20)
- Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia‐associated antigens (2015) (19)
- Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition (2017) (19)
- Tissue distribution of blood group membrane proteins beyond red cells: evidence from cDNA libraries. (2006) (18)
- Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy (2014) (18)
- One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study (2020) (18)
- A T cell receptor-associated GTP-binding protein triggers T cell receptor-mediated granule exocytosis in cytotoxic T lymphocytes. (1988) (18)
- Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients (2015) (18)
- Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study. (1998) (17)
- Clonal hematopoiesis as defined by polymorphic X-linked loci occurs infrequently in aplastic anemia. (1995) (17)
- Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system (2009) (17)
- Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. (1996) (16)
- Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies (2021) (16)
- The role of mitochondrial targeting in arsenic trioxide‐induced apoptosis in myeloid cell lines (2004) (16)
- HLA Matching in Unrelated Stem Cell Transplantation up to Date (2019) (16)
- Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines. (2004) (16)
- Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria (2009) (16)
- Autologous Mesenchymal Stroma Cells Are Superior to Allogeneic Ones in Bone Defect Regeneration (2018) (16)
- Endocrine effects of recombinant interleukin 6 in man. (1996) (16)
- Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry (2018) (16)
- Complement Activation and Organ Damage After Trauma—Differential Immune Response Based on Surgical Treatment Strategy (2020) (15)
- B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. (2014) (15)
- Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow) (2011) (15)
- Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary (2020) (15)
- Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients (2017) (14)
- Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation. (1993) (14)
- Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119(23):5391-5396. (2013) (14)
- The frequency of DRB1*1454 in South German Caucasians. (2010) (14)
- Terminal Complement Inhibitor Eculizumab Improves Complement-Mediated Platelet Consumption and Thrombocytopenia in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). (2009) (14)
- Comparison of allogeneic bone marrow and peripheral blood stem cell transplantation for aplastic anemia : collaborative study of european blood and marrow transplant group (EBMT) and international bone marrow transplant registry (IBMTR) (2003) (14)
- Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial (2021) (14)
- Serum Erythropoietin and Thrombopoietin Levels in Patients with Essential Thrombocythaemia (2000) (14)
- Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry (2017) (14)
- Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread (2018) (13)
- Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)—a report on phase III (2019) (13)
- High Dose Convalescent Plasma in COVID-19: Results from the randomized Trial CAPSID (2021) (13)
- Next-Generation Sequencing Technologies in Blood Group Typing (2019) (13)
- Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab) (2013) (13)
- Osteoarthritic Milieu Affects Adipose‐Derived Mesenchymal Stromal Cells (2019) (13)
- Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation (2005) (12)
- Iron-loaded PLLA nanoparticles as highly efficient intracellular markers for visualization of mesenchymal stromal cells by MRI. (2014) (12)
- Inflammatory response of mesenchymal stromal cells after in vivo exposure with selected trauma-related factors and polytrauma serum (2019) (12)
- Sequence-based typing of major histocompatibility complex class I chain-related gene A alleles by use of exons 2-5 information. (2011) (12)
- Clonal Hematopoiesis as Defined by Polymorphic X-Linked Loci Occurs Infrequently in Aplastic Anemia (1995) (12)
- Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients (2019) (12)
- DNA methylation in PRDM8 is indicative for dyskeratosis congenita (2016) (12)
- Osteonecrosis of the Femoral Head Safely Healed with Autologous, Expanded, Bone Marrow-Derived Mesenchymal Stromal Cells in a Multicentric Trial with Minimum 5 Years Follow-Up (2021) (12)
- Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. (2004) (12)
- International Forum on GMP‐grade human platelet lysate for cell propagation (2018) (11)
- Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany. (2009) (11)
- Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses (2017) (10)
- Systemic recovery and therapeutic effects of transplanted allogenic and xenogenic mesenchymal stromal cells in a rat blunt chest trauma model. (2018) (10)
- Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas (2016) (10)
- Desmoplakin and KIF20B as target antigens in patients with paroxysmal nocturnal haemoglobinuria (2010) (10)
- Deregulated expression of circular RNAs in acute myeloid leukemia. (2018) (10)
- Congenital CD59 Deficiency. (2015) (10)
- Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56brightCD16+NKp80+/- In-Vitro and Express KIR2DL2/DL3 and KIR3DL1 (2021) (9)
- Complement and the prothrombotic state. (2021) (9)
- Necrosis-Associated Factors (DAMPs) Including S100A4 Used to Pulse Dendritic Cells (DCs) Induce Regulatory T cells (2012) (9)
- Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia (2019) (9)
- Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients (2022) (9)
- Quality of tumor lysates used for pulsing dendritic cells is influenced by the method used to harvest adherent tumor cells (2011) (9)
- Typically asymptomatic but with robust antibody formation: Childrens unique humoral immune response to SARS-CoV-2 (2021) (9)
- Random survey for RHD alleles among D positive Europeans (2004) (9)
- Donor selection and release criteria of cellular therapy products (2013) (9)
- Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry. (2010) (8)
- BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents (2021) (8)
- Emergence of CD 52-, Phosphatidylinositolglycan-Anchor-Deficient T Lymphocytes After In Vivo Application of Campath-1 H for Refractory B-Cell Non-Hodgkin Lymphoma (2000) (8)
- [Paroxysmal nocturnal hemoglobinuria. Clinical experiences with 40 patients at one center over 25 years]. (2008) (8)
- HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival. (2012) (8)
- The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis (2021) (8)
- Systemic and Cardiac Alterations After Long Bone Fracture (2020) (8)
- Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients (2021) (8)
- The Monoclonal Anti‐CD157 Antibody Clone SY11B5, Used for High Sensitivity Detection of PNH Clones on WBCs, Fails to Detect a Common Polymorphic Variant Encoded by BST‐1 (2018) (8)
- Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study. (2006) (8)
- Autoantibodies against Progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill COVID-19 (2021) (8)
- A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia. (1997) (8)
- The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria. (2006) (7)
- One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients (2022) (7)
- Efficient retrovirus-mediated transduction of primitive human peripheral blood progenitor cells in stroma-free suspension culture (2001) (7)
- CD34 selected alloPBSCT and adoptive immunotherapy (2000) (7)
- Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (2010) (7)
- ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase (2018) (7)
- Clinical-grade mesenchymal stromal cells produced under various GMP processes differ in their immunomodulatory properties : Standardization of immune quality controls (2014) (7)
- Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces (2021) (7)
- Evidence for a paracrine pathway of B‐cell stimulation in hairy cell leukaemia (1995) (7)
- Preparation of granulocyte concentrates by apheresis (2010) (7)
- Cyclosporin A in aplastic anemia — report of a workshop (1992) (7)
- Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition (2020) (6)
- Use of G-CSF in Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine Increases Neutrophils and Decreases Infection Rates and Hospitalization Days but Does Not Improve Long-Term Outcome: Results of a Prospective, Randomized Clinical Trial of the EBMT. (2009) (6)
- Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies (2017) (6)
- Matched Sibling Transplants for Aplastic Anemia: Survival Advantage for Marrow Vs Peripheral Blood Transplants, In All Age groups (2010) (6)
- The Management of Paroxysmal Nocturnal Haemoglobinuria – Recent Advances in Diagnosis and Treatment, and New Hope for Patients (2009) (6)
- Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies (2019) (6)
- Hepcidin/Ferritin Quotient Helps to Predict Spontaneous Recovery from Iron Loss following Blood Donation (2015) (6)
- Aplastic Anemia: Immunosuppressive treatment of aplastic anemia (1999) (6)
- Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: An on Going Joint Study of the AAWP EBMT Group and the French Society of Hematology (2008) (6)
- Identification of Elite Neutralizers With Broad and Potent Neutralizing Activity Against Human Cytomegalovirus (HCMV) in a Population of HCMV-Seropositive Blood Donors (2018) (6)
- Gender, cholinesterase, platelet count and red cell count are main predictors of peripheral blood stem cell mobilization in healthy donors (2019) (6)
- Stimulus-dependent triggering or inhibition of cytotoxicity in human cytotoxic T lymphocytes by activators of protein kinase C. (1986) (6)
- A two‐step screening approach for the identification of blood donors with highly and broadly neutralizing capacities against human cytomegalovirus (2017) (6)
- Subcutaneous IL-2 and Low-Dose IFN-α2a in the Treatment of Unselected Patients with Advanced Renal Cell Cancer (1994) (5)
- Immunosuppressive therapy for transplant-ineligible aplastic anemia patients (2015) (5)
- Outcome of Patients with Aplastic Anemia Given First Line Transplantion or Immunosuppression in the Last Decade: A Report from European Group for Blood and Marrow Transplantation (EBMT). (2006) (5)
- Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA). (2008) (5)
- INTRACORONARY STEM CELL THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION – 36 MONTHS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL WITH SERIAL MRI FOLLOW-UPS (2012) (5)
- Monocytes express the serine protease granzyme B - potential involvement in antigen processing and presentation. (P5033) (2013) (5)
- New cellular therapies: Is there a role for transfusion services? (2009) (5)
- Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products (2008) (5)
- Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation (2016) (5)
- SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays (2022) (5)
- [Convalescent Plasma for Treatment of Severe COVID-19: Rationale and Designing of a Randomized, Open-Label Clinical Trial of Convalescent Plasma Compared to Best Supportive Care (CAPSID Trial)] (2020) (5)
- Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay (2018) (5)
- Enhanced stimulation of antigen‐specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti‐programmed death 1 antibody (2022) (5)
- Transfusion Support (2018) (5)
- Fracture Healing Is Delayed in Immunodeficient NOD/scid-IL2R gamma(null)(c) Mice (2016) (5)
- Flow Cytometric Analysis of GPI‐deficient Cells for the Diagnosis ofParoxysmal Nocturnal Hemoglobinuria (PNH) (2003) (5)
- HLA‐DRB4*01:14 is a null allele, and renamed HLA‐DRB4*01:14N (2020) (5)
- Granulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantation (2020) (4)
- A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria (2018) (4)
- First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001‐2012 (2016) (4)
- Therapy of Acquired Aplastic Anemia (AA) with Rabbit Antithymocyte Globulin (rATG): A Retrospective Analysis by the Working Group on Non-Malignant Disorders of Hematopoiesis of the German Society of Hematology and Oncology (DGHO), (2011) (4)
- Long-term safety of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (2012) (4)
- Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria (2014) (4)
- Empfehlungen zur Diagnostik der Paroxysmalen nächtlichen Hämoglobinurie: deutsch – österreichischer Konsensus/Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian consensus (2011) (4)
- Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation (2022) (4)
- Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (2021) (4)
- Transduction Enhancers Enable Efficient Human Adenovirus Type 5-Mediated Gene Transfer into Human Multipotent Mesenchymal Stromal Cells (2021) (4)
- A novel allele of the atypical chemokine receptor 1 (ACKR1) gene containing the nucleotide change c.126 T>G (p.42Glu) encodes a third Duffy blood group protein sequence antithetical to that encoding Fya and Fyb antigens (2019) (4)
- Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects (2018) (4)
- HEMISPHERIC STROKE DOES NOT MOBILIZE CD34+ HEMATOPOIETIC STEM CELLS INTO THE PERIPHERAL BLOOD (2009) (4)
- Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction. (2021) (4)
- Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation (2017) (4)
- Development Of a Disease Specific Quality Of Life Questionnaire For Patients With Aplastic Anemia and/Or Paroxysmal Nocturnal Hemoglobinuria (QLQ-AA/PNH) (2013) (4)
- Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation from International PNH Registry Patient Data (2021) (4)
- OP04 Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: Shepherd Phase III clinical study results (2007) (3)
- Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA (2008) (3)
- HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation (2021) (3)
- Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia (2009) (3)
- SARS-CoV2 mRNA Vaccine-Specific B-, T- and Humoral Responses in Adolescents After Kidney Transplantation (2022) (3)
- Random survey for RH allele polymorphism among 50 native Tibetans (2006) (3)
- Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency. (2009) (3)
- Developments and Quality Assurance in Stem Cell Transplantationfrom a German National Registry (2006) (3)
- Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals (2021) (3)
- The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria (2022) (3)
- TNFA promoter alleles--frequencies and linkage with classical HLA genes in a South German Caucasian population. (2012) (3)
- Withdrawn: Standard first-line immunosuppression for acquired severe aplastic anemia in adults. (1969) (3)
- Validation of Microbiological Testing of Cellular Medicinal Products Containing Antibiotics (2019) (3)
- B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients (2022) (3)
- Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy. (2007) (3)
- Circulating Erythropoietin Levels in Pathophysiological Conditions a (1994) (3)
- Effects of Circulating HMGB-1 and Histones on Cardiomyocytes–Hemadsorption of These DAMPs as Therapeutic Strategy after Multiple Trauma (2020) (3)
- Resequencing of four novel alleles with nanopore technology (2018) (3)
- S863 ONE-YEAR EFFICACY OF RAVULIZUMAB (ALXN1210) IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAIVE TO COMPLEMENT INHIBITORS (2019) (3)
- Successful treatment of partial graft failure after matched unrelated donor stem cell transplantation by a combination of ancestim (stem cell factor) and granulocyte colony stimulating factor in a patient with heavily pre-treated chronic lymphocytic leukemia (2008) (3)
- Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study (2012) (3)
- Medullary histiocytosis following treatment of severe aplastic anemia with recombinant human interleukin-3 in combination with antilymphocyte globulin, cyclosporin A, and methylprednisolone (1991) (3)
- Human immunodeficiency virus 1 dual‐target nucleic acid technology improves blood safety: 5 years of experience of the German Red Cross blood donor service Baden‐Württemberg–Hessen (2018) (3)
- Aplastic Anemia: Guidelines for treating aplastic anemia (1999) (3)
- GMP-Grade Large-Scale Expansion of Bone-Marrow- (BM) Derived Human Mesenchymal Stem/Stroma Cells (MSC): Comparison of Efficacy of Different Expansion Systems and Role of Cytokines/Chemokines (2010) (2)
- Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry (2010) (2)
- Paracrine regulation of B-cell growth in hairy cell leukemia. (1994) (2)
- Higher risk for chronic graft‐versus‐host disease (GvHD) in HLA‐G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study (2022) (2)
- Efficacy of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and High Disease Activity with or without History of Aplastic Anemia in the International PNH Registry (2017) (2)
- Granzyme B Is a Key Regulator of Plasmacytoid Dendritic Cell Immunogenicity (2014) (2)
- BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages (2022) (2)
- Specific Immune Responses for Leukemia-Associated Antigens Against Myeloid Leukemic Cells Are Increased By Immune Checkpoint Inhibition (2016) (2)
- Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry (2018) (2)
- High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection (2022) (2)
- Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST). (2009) (2)
- Granulocyte-macrophage colony-stimulating factor in the sera of patients with aplastic anemia (1993) (2)
- Outcome Of Aplastic Anemia In Adolescence. A Survey Of The Severe Aplastic Anemia Working Party (SAAWP) Of The European Blood and Bone Marrow Transplant Group (EBMT) (2013) (2)
- Response to Zimmermann et al (2010) (2)
- Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML (2020) (2)
- Clinical characteristics of classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients: a comparison with classic PNH in adults. An international PNH registry study (2011) (2)
- Poly-L-Lactic Acid (PLLA) Iron Loaded Nanoparticles for MRI Cell Labelling (2009) (2)
- [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment]. (2009) (2)
- An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial (2020) (2)
- Human mesenchymal stem cells constitutively express the serine protease granzyme B. (P1097) (2013) (2)
- Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)² (2020) (2)
- Corrigendum to: Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)‐ and anti‐CD95‐induced apoptosis in myeloid cells (FEBS 29005) [FEBS Letters 578 (2004) 85–89] (2005) (2)
- CD90 Is Dispensable for White and Beige/Brown Adipocyte Differentiation (2020) (2)
- Immune Plasma for the Treatment of COVID-19: Lessons Learned so far (2022) (2)
- ATP promotes immunosuppressive MSCs inhibiting lymphocyte proliferation and expressing indoleamine dioxygenase (2017) (1)
- Evaluation of factor H (FH), miniFH and the Fc-fusion protein Fc-miniFH in pharmacokinetic studies and different in vitro models of complement mediated diseases (2016) (1)
- Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks (2020) (1)
- Bone as a Target for the Complement System (2012) (1)
- Complete Loss of HLA Class I Heterozygosity in a Patient with Acute Myeloid Leukemia (2015) (1)
- Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study (2011) (1)
- The Factor H splice variant FHL-1 contributes substantially to alternative pathway regulation, but is not specific for the host marker sialic acid (2017) (1)
- P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION (2022) (1)
- Complement- and inflammasome-mediated autoinflammation-paroxysmal nocturnal hemoglobinuria (2019) (1)
- COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria (2020) (1)
- HIV triggers interleukin 21-mediated induction of granzyme B-secreting B cells with antiviral properties (105.18) (2012) (1)
- Erytra blood group analyser and kode technology testing of SARS‐CoV‐2 antibodies among convalescent patients and vaccinated individuals (2021) (1)
- the treatment of patients with paroxysmal nocturnal hemoglobinuria Multicenter phase 3 study of the complement inhibitor eculizumab for (2008) (1)
- Enhanced Stimulation of Antigen-Specific Immune Responses Against NPM1-Mutated AML (2021) (1)
- Absence of CC chemokine receptors 2a and 2b from human adipose lineage cells (2013) (1)
- Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry (2017) (1)
- [Aplastic anemia: Current state of diagnosis and treatment]. (2015) (1)
- Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry (2015) (1)
- Tumor-infiltrating lymphocytes in breast cancer tissue comprise granzyme B-expressing B cells with cytotoxic potential (2012) (1)
- HIV triggers interleukin 21-mediated induction of granzyme B-secreting B cells with T cell regulatory potential. (P1441) (2013) (1)
- Expression of PD-L1 in Leukemic Progenitor Cells Defines NPM1 Mutated AML As a Potential Subgroup for PD1/PD-L1 Directed Immunotherapy (2018) (1)
- [Diagnosis of hemolysis and differential hemolytic anemia diagnosis]. (1998) (1)
- Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure (2011) (1)
- A novel approach for large-scale manufacturing of small extracellular vesicles from bone marrow-derived mesenchymal stromal cells using a hollow fiber bioreactor (2023) (1)
- Donors with KIR-Bx Haplotypes Improve Outcome of Unrelated Hematopoietic Stem Cell Transplantation for Recipients with a Myeloid Malignant Disease and a C1 Ligand Phenotype (2015) (1)
- Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry (2022) (1)
- Results from a Phase 3, Multicenter, Noninferiority Study of Ravulizumab (ALXN1210) versus Eculizumab (ECU) in Adult Patients (pts) with Paroxysmal Nocturnal Hemoglubinuria (PNH) Naive to Complement Inhibitors (CI) (2019) (1)
- Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis (2022) (1)
- Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT (2018) (1)
- Long term outcomes in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) with sustained eculizumab treatment (2012) (1)
- Response to Comment on “Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1” (2019) (1)
- Rationale Therapie mit Erythrozytenkonzentraten – Update 2020 (2021) (1)
- 189Mechanistic evidence for incomplete terminal pathway inhibition under eculizumab during strong complement activation (2016) (1)
- Unrelated Donor Transplants for Severe Aplastic Anemia: A Report from the EBMT SAA Working Party. (2007) (1)
- Direct Antiglobulin Test, Ferritin and GPI-Negative Cell Populations in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Eculizumab Therapy: Extravascular Hemolysis Unmasked by Efficient Eculizumab-Mediated Inhibition of Intravascular Hemolysis. (2008) (1)
- The ethics of wasting the donor’s gift of buffy coat: response to E.C. Vamvakas (2011) (1)
- Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19 (2022) (1)
- Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells (2022) (1)
- Extended loci histocompatibility matching in HSCT—Going beyond classical HLA (2021) (1)
- Effect of phosphonate-functionalised nanoparticles on human mesenchymal stem cells and osteoclasts (2011) (1)
- 162-P: HLA-A and -B low expression and null alleles in 10690 unrelated bone marrow donors (UBMD) (2008) (1)
- INTRACORONARY STEM CELL THERAPY AFTER MYOCARDIAL INFARCTION - TWELVE MONTHS FOLLOW-UP OF A RANDOMIZED, RIGOROUS DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL (2010) (1)
- Tumor-infiltrating lymphocytes in breast cancer tissue comprise granzyme B-expressing B cells with cytotoxic potential (127.23) (2012) (1)
- Effects of Minor Histocompatibility Antigen Mismatches on Clinical Outcome After Unrelated Hematopoietic Stem Cell Transplantation (HSCT) in 320 Recipients and Their Unrelated Donors – a Multivariate Analysis (2011) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies. (2009) (1)
- Outcome of Aplastic Anemia in Children. A Survey On Behalf of the SAA and PDWP of the EBMT (2012) (1)
- Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor (2016) (1)
- Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors (2023) (0)
- 347 Successful treatment of transfusional iron overload in MDS patients with deferasirox as indicated by Liver-MRI: A German, multi-center trial (2011) (0)
- [Rational therapy with erythrocyte concentrates - Update 2022]. (2022) (0)
- P043 HLA-DPB matching and donor cytomegalovirus positive (CMV+) status: An “unconventional alliance” associated with a decreased relapse incidence in unrelated hematopoietic stem cell transplantation (UHSCT) (2017) (0)
- Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial (2023) (0)
- Heterozygous RTEL1 variants are associated with bone marrow failure in cryptic dyskeratosis congenita - first results from the Aachen telomere registry (2017) (0)
- Oral Sessions (2014) (0)
- Editorial Board / Contents / Imprint / Guidelines for Authors (2015) (0)
- COMPARISON BETWEEN ELISA-CROSSMATCH AND THE CLASSICAL MICROLYMPHOCYTOTOXICITY CROSSMATCH ASSAY: 2281 (2008) (0)
- AbstractPoster session I: Genetic polymorphism (MHC/MIC/cytokines)106-P: A PCR-SSP method for NOD2/CARD15 gene 3 SNP analysis (2006) (0)
- Recommendations of the DGTI for the Use of Hydroxyethyl Starch as a Sedimentation Accelerator in the Granulocytapheresis (2019) (0)
- P132 Differential HLA-C expression in caucasians: Useful data from direct HLA-protein measurements in 188 healthy German donors (2017) (0)
- Aplastic Anemia: Preface (1999) (0)
- Inhalt Band 35, Heft 3, June 2008 (2008) (0)
- PS1117 NO CHANGE IN THE EFFECTIVENESS OF IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH PNH AND AA RECEIVING CONCOMITANT ECULIZUMAB (2019) (0)
- The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation. (2009) (0)
- + /IDO+ Stromal Cell Induction of IL-10 S100A4 and Uric Acid Promote Mesenchymal (2014) (0)
- Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation (2022) (0)
- Contents Vol 42, 2015 (2015) (0)
- The fate of B cells in HIV infection - shifting the balance from plasma cell towards regulatory B cell (Breg) differentiation (LYM6P.776) (2014) (0)
- Laboratory examination of hematologic diseases at the interdisciplinary hematologic competence center (IHK) of Innsbruck of the clinic for hemato-oncology V of the university hospital Innsbruck and the central laboratory of the university hospital Innsbruck (ZIMCL)1) (2013) (0)
- Hämatologische Labordiagnostik im interdisziplinären hämatologischen Kompetenzzentrum (IHK) der hämatologisch onkologischen Klinik V der Universitätsklinik Innsbruck und des Zentrallabors der Universitätsklinik Innsbruck/Laboratory examination of hematologic diseases in the Interdiscipline Hematolog (2013) (0)
- IL-21-Mediated Generation of Human Regulatory B Cells Occurs Independently of CD40 Signaling (2014) (0)
- Monitoring the in-Vivo Expansion and Persistence of CAR-T Cells As a Tool to Help Decision Making in Patients with Aggressive B-Cell Lymphoma (2022) (0)
- Coating strategies for expansion of mesenchymal stromal cells in a hollow-fibre bioreactor (2020) (0)
- Interleukin-21-Induced Granzyme B-Expressing B Lymphocytes Infiltrate Tumors and Regulate T Cells (2012) (0)
- evidence of a mutational hotspot nocturnal hemoglobinuria ( AA / PNH ) : a high incidence of multiple The spectrum of PIG-A gene mutations in aplastic anemia / paroxysmal (2002) (0)
- OR26. Investigating the impact of patient’s non-shared HLA-C Allotype expression levels in A 9/10 Single HLA-C mismatched hematopoieticstem cell transplantationsetting using two different HLA-C Expression proxy models (2018) (0)
- Robust and durable serological response following pediatric SARS-CoV-2 infection (2022) (0)
- Monitoring of Engraftment and Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Based on Lineage Specific Short-Tandem-Repeat Chimerism (2015) (0)
- OR38 Beneficial effect of HLA-E mismatches on the outcome of hematopoietic stem cell transplantation in acute lymphoblastic leukemia patients (2015) (0)
- OR38 Beneficial effect of HLA-E mismatches on the outcome of hematopoietic stem cell transplantation in acute lymphoblastic leukemia patients (2015) (0)
- SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays (2023) (0)
- Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas (2023) (0)
- IMMUNOBIOLOGY Incomplete inhibition by eculizumab : mechanistic evidence for residual C 5 activity during strong complement activation (2017) (0)
- [Value of convalescent plasma in the therapy of COVID-19]. (2023) (0)
- Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate (2014) (0)
- Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation (2011) (0)
- Quality Controls of Immune Regulatory Properties of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells for Clinical Use (European multicenter study CASCADE), (2011) (0)
- Key Point : A carrier of a deleterious splice site mutation in PIGT acquired a second hit in PIGT and developed PNH (2013) (0)
- ADIPOSE MESENCHYMAL STROMAL CELL CHARACTERISTICS ARE DIFFERENTLY MODULATED BY OSTEOARTHRITIC MILIEU (2018) (0)
- LEVELS OF SMICA, AS DETECTED BY A HIGHLY SENSITIVE LUMINEX ASSAY, HIGHLY ASSOCIATE WITH GRAFT REJECTION: 1552 (2010) (0)
- Missing KIR-Ligands in Single Mismatched Unrelated Hematopoietic Stem Cell Transplantation (2013) (0)
- A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria. (2009) (0)
- Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation (2022) (0)
- Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian Consensus1) (2012) (0)
- HIV Triggers Interleukin 21-Mediated Induction of Granzyme B-Secreting B Cells with Regulatory and Antiviral Potential (2012) (0)
- globulin with or without cyclosporine A for treatment of aplastic anemia Eleven years follow-up of a randomized trial comparing antithymocyte (2013) (0)
- PF348 LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL (2019) (0)
- transplantation: a retrospective collaborative analysis High-resolution HLA matching in hematopoietic stem cell (2013) (0)
- ATP, HMGB1, and S100A4 promote immunosuppressive mesenchymal stromal cells by enhancing their kynurenine production. Impact of necrosis on tumor-associated MSCs (2019) (0)
- P046 Deconstructing HLA-C mismatch in hematopoietic stem cell transplantation (2016) (0)
- CD27+IgD− B cells in the peripheral blood of colorectal cancer patients: on anti-tumor or tumor-protective mission? (2014) (0)
- Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposure (2022) (0)
- MEDICAL THEORY AND ACTING AS PHYSICIAN IN THE CLINICAL MEDICAL-EDUCATION - EXPERIENCES DURING CLERKSHIP IN INTERNAL-MEDICINE (1993) (0)
- Reducing agents such as ascorbic acid or N-acetylcysteine support the chemotactic and proliferation-inducing effect of S100A4 on mesenchymal stromal cells (P2165) (2013) (0)
- Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells (2022) (0)
- Induction of apoptosis and growth inhibition in myeloid malignancies by arsenic trioxide (As203) (2000) (0)
- Necrosis associated factors (S100A4 and uric acid) promote accumulation of MSCs which induce IL10+/IDO+ lymphocytes (TUM7P.949) (2014) (0)
- Brief Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT) (2007) (0)
- Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations (2022) (0)
- MYOCARDIAL ISCHEMIA AND INFARCTION INTRACORONARY STEM CELL THERAPY AFTER MYOCARDIAL INFARCTION - TWELVE MONTHS FOLLOW- UP OF A RANDOMIZED, RIGOROUS DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL (2010) (0)
- Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls (2012) (0)
- Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells. (2006) (0)
- ' s response to reviews Title : Sepsis induced changes of adipokines and cytokines . Septic patients compared to morbidly obese patients (2010) (0)
- HIV-Infected T Cells Induce Granzyme B-Secreting Regulatory B Cells in An Interleukin 21-Dependent Fashion, (2011) (0)
- Interleukin-21-induced granzyme B-expressing B lymphocytes regulate T cells and infiltrate tumors (P1088) (2013) (0)
- NO and ROS in immune responses (WS-005) Chairpersons: Hiroyasu Nakano, Junji Yodoi (2010) (0)
- 197-P: Comprehensive antibody-screening in apheresis donors with suspected risk for induction of TRALI (2008) (0)
- APLASTIC ANAEMIA (2001) (0)
- Supportive Care in Aplastic Anemia (2017) (0)
- Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation (2022) (0)
- Drug-induced agranulocytosis in the Berlin case–control surveillance study (2013) (0)
- Quality Controls Of Immune Regulatory Properties Of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells For Clinical Use (2013) (0)
- Aplastic Anemia: Treatment of acquired aplastic anemia (1999) (0)
- Aplastic Anemia: The interrelation between aplastic anemia and paroxysmal nocturnal hemoglobinuria (1999) (0)
- Knockout of adenylate kinase 2 in mice leads to early embryonic lethality and to profound anemia in a conditional setting (2017) (0)
- 21 FUNCTIONAL RELEVANT TELOMERASE MUTATIONS ASSOCIATE WITH CIRRHOSIS FORMATION IN PATIENTS WITH CHRONIC LIVER DISEASE (2010) (0)
- A Novel Tissue and Stem Cell Specific TERF1 Splice Variant Is Downregulated in Tumour Cells (2019) (0)
- CD59 is a blood group antigen (2013) (0)
- The Role of HLA-E Polymorphism in Acute Leukemia Patients Receiving a 10/10 HLA Matched Unrelated HSCT (2018) (0)
- PIGT mutation and a somatic mutation in A case of paroxysmal nocturnal hemoglobinuria caused by a germline (2013) (0)
- Advancing approaches for bone regeneration using freshly shipped marrow human mesenchymal stromal/stem cell produced into several european cGMP facilities (2013) (0)
- Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT (2021) (0)
- Chapter 9:Culturing Non-hematopoietic Mesenchymal Stromal Cells and Requirements of GMP in Stem Cell-based Therapies (2010) (0)
- 9-P: Comparison between ELISA and CDC crossmatch (2008) (0)
- Clinical implications of incomplete C5 inhibition by Eculizumab illustrated by experimental and clinical data from 15 PNH patients (2018) (0)
- Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria (2013) (0)
- Specific effects of osteoarthritic milieu and hypoxic conditions on adipose mesenchymal stromal cell migration and cytokine receptors expression (2020) (0)
- Interleukin-21-induced granzyme B-expressing B lymphocytes regulate T cells and infiltrate human solid tumors (2012) (0)
- Aplastic Anemia: Role of cytokines in the treatment of aplastic anemia (1999) (0)
- Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension (2020) (0)
- Serum Erythropoietin Levels in Aplastic Anemia Determined by ELISA (1992) (0)
- SARS-CoV2 mRNA-vaccination-induced Immunological Memory in Human Non-Lymphoid and Lymphoid Tissues (2023) (0)
- Analysis Of Leukemic Stem Cell Population Comparing NPM1wt and NPM1mut AML Patients and Potential Therapeutic Targets (2013) (0)
- 98-P: TNF-a PROMOTER ALLELES WITHIN CONSERVED HLA-HAPLOTYPES (2012) (0)
- Fatal Puumala Hantavirus Infection in a Patient with Common Variable Immunodeficiency (CVID) (2023) (0)
- Aplastic Anemia: Index (1999) (0)
- Proaerolysin Multi Color Flow-Fish Reveals Shortened Telomere Length in GPI− as Compared to GPI+ Granulocytes from Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). (2004) (0)
- 105-P: NOD2/CARD15 SNP genotyping by Luminex and impact on the outcome of unrelated stem cell transplantation (2008) (0)
- Microenvironment and Immunology Interleukin 21 – Induced Granzyme B – Expressing B Cells In fi ltrate Tumors and Regulate T Cells (2013) (0)
- Bone Marrow Failure in PNH (2017) (0)
- Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies (2020) (0)
- Shared and Divergent Stimulatory Effects of S100A4 and Uric Acid on Proliferation and Chemotaxis of Mesenchymal Stem Cells (MSCs). Interplay Between Necrotic Tumor Material and Immunosuppressive MSCs within Tumor Microenvironment (2011) (0)
- TRANSPLANTATION Matching for the MICA-129 polymorphism is bene fi cial in unrelated hematopoietic stem cell transplantation (2016) (0)
- Mesenchymale Stromazellen auf demWeg zur klinischen Anwendung : Update 2018 Mesenchymal Stromal Cells on Their Way from Bench to Bedside : Update 2018 (2018) (0)
- Paroxysmal nocturnal hemoglobinuria revisited: news on pathophysiology, clinical course and treatment (2015) (0)
- Kongressberichte – Congress Reports (1994) (0)
- Mesenchymal Stromal Cells Respond to Necrotic Material within Tumor Microenvironment with Regard to Proliferation and Chemotaxis (0)
- POS0050 B CELL CHARACTERISTICS AT BASELINE PREDICT HUMORAL RESPONSE UPON SARS-CoV-2 VACCINATION AMONG PATIENTS TREATED WITH RITUXIMAB (2022) (0)
- How do we treat? Clinical haemotherapy: platelet transfusion (2010) (0)
- Working Party Aplastic Anaemia (2001) (0)
- Stressed Cells Molecular Pattern Molecules Derived from Eosinophils Oxidize Damage-Associated (2009) (0)
- Osteoarthritic milieu and hypoxia exert specific effects on adipose mesenchymal stromal cell migration and cytokine receptor expression (2019) (0)
- Immunosuppressive treatment of aplastic anemia:Comparative trial evaluating antilymphocyte globulin versus antilymphocyte globulin and ciclosporin A (1992) (0)
- Effects of a novel ceramic biomaterial on immune modulatory properties and differentiation potential of mesenchymal stromal cells (2013) (0)
- Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial (2018) (0)
- Correlating ex vivo and in vivo osteogenic assays for quality control of clinically destined cGMP grade BM-MSC (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Hubert Schrezenmeier?
Hubert Schrezenmeier is affiliated with the following schools:
